Drug Profile
Research programme: sulindac derivative - Medicon/Stony Brook University
Alternative Names: MDC-922Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medicon; State University of New York at Stony Brook
- Class Indenes; Small molecules
- Mechanism of Action Cell cycle protein inhibitors; Cyclo-oxygenase 1 modulators; Cyclo-oxygenase 2 modulators; Mitogen-activated protein kinase modulators; NF-kappa B modulators; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 21 Apr 2010 Early research in Cancer in USA (unspecified route)
- 21 Apr 2010 Pharmacodynamics data from in vitro trials in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)